19. Dezember 2023
Published by Paul Wolfrom on 19. Dezember 2023
Categories

LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc’s Innovative Vaccine Candidate Against Staphylococcus aureus

LimmaTech receives an exclusive clinical development license from AbVacc for a multivalent, toxoid vaccine candidate to prevent infections caused by Staphylococcus aureus, the leading cause of […]
Do you like it?0
Read more
9. Oktober 2023
Published by Paul Wolfrom on 9. Oktober 2023
Categories

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

Schlieren (Zurich), October 9, 2023 – LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led […]
Do you like it?0
Read more
20. Juli 2023
Published by Paul Wolfrom on 20. Juli 2023
Categories

LimmaTech Biologics Appoints Franz-Werner Haas as CEO to Lead Company into Next Stage of Corporate Growth

LimmaTech has leveraged a novel technology platform to produce a pipeline of vaccines against multi-resistant bacterial infections that present global health threats
Do you like it?0
Read more
12
Next page